Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:APNHYOTCMKTS:CHMEOTCMKTS:GBIMOTCMKTS:IPAH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPNHYAspen Pharmacare$6.99+3.3%$6.69$5.76▼$13.69N/A0.96248 shs122 shsCHMEChina Medicine$0.00$0.00$0.00▼$0.01N/A213.3375 shsN/AGBIMGlobeimmune$0.00$0.00$0.00▼$0.00N/A-269.17N/A410 shsIPAHInterpharm$0.00$0.00▼$0.00N/A59.47N/AN/AThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPNHYAspen Pharmacare0.00%+2.91%+1.81%-6.66%-44.29%CHMEChina Medicine0.00%0.00%+50.00%+200.00%+200.00%GBIMGlobeimmune0.00%0.00%-50.00%-50.00%-50.00%IPAHInterpharm0.00%0.00%0.00%0.00%+4,000.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPNHYAspen PharmacareN/AN/AN/AN/AN/AN/AN/AN/ACHMEChina MedicineN/AN/AN/AN/AN/AN/AN/AN/AGBIMGlobeimmuneN/AN/AN/AN/AN/AN/AN/AN/AIPAHInterpharmN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPNHYAspen Pharmacare 0.00N/AN/AN/ACHMEChina Medicine 0.00N/AN/AN/AGBIMGlobeimmune 0.00N/AN/AN/AIPAHInterpharm 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPNHYAspen Pharmacare$2.39BN/AN/AN/AN/AN/ACHMEChina MedicineN/AN/AN/AN/AN/AN/AGBIMGlobeimmuneN/AN/AN/AN/AN/AN/AIPAHInterpharmN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPNHYAspen Pharmacare$235.61MN/A0.006.92N/AN/AN/AN/A9/3/2025 (Estimated)CHMEChina MedicineN/AN/A0.00∞N/AN/AN/AN/AN/AGBIMGlobeimmuneN/AN/A0.00∞N/AN/AN/AN/AN/AIPAHInterpharmN/AN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPNHYAspen Pharmacare$0.121.72%N/AN/AN/ACHMEChina MedicineN/AN/AN/AN/AN/AGBIMGlobeimmuneN/AN/AN/AN/AN/AIPAHInterpharmN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPNHYAspen Pharmacare0.362.351.25CHMEChina MedicineN/AN/AN/AGBIMGlobeimmuneN/AN/AN/AIPAHInterpharmN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPNHYAspen PharmacareN/ACHMEChina MedicineN/AGBIMGlobeimmuneN/AIPAHInterpharmN/AInsider OwnershipCompanyInsider OwnershipAPNHYAspen PharmacareN/ACHMEChina Medicine29.70%GBIMGlobeimmune23.50%IPAHInterpharm58.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPNHYAspen Pharmacare9,350N/AN/ANot OptionableCHMEChina Medicine280N/AN/ANot OptionableGBIMGlobeimmune3N/AN/ANot OptionableIPAHInterpharm670N/AN/ANot OptionableAPNHY, CHME, GBIM, and IPAH HeadlinesRecent News About These CompaniesNo headlines for this company have been tracked by MarketBeat.comMedia Sentiment Over TimeAPNHY, CHME, GBIM, and IPAH Company DescriptionsAspen Pharmacare OTCMKTS:APNHY$6.99 +0.22 (+3.27%) As of 07/3/2025Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anesthetics, muscle relaxants, and topical agents under the Anaesthetics brand; and a range of injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand. It also offers branded consumer, prescription, and over-the-counter products under the regional brands, such as Circadin, Foxair, Maltofer, Mybulen, and Zyloric for various types of anesthetic comprises sleeping aid, respiratory, iron supplement, analgesic, and uric acid production inhibitor. In addition, the company manufactures and sells active pharmaceutical ingredients and finished dose form products to third-party customers. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.China Medicine OTCMKTS:CHME$0.0003 0.00 (0.00%) As of 07/3/2025China Medicine Corporation produces and distributes prescription and over the counter drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. The company offers various products for applications, including oncology, high blood pressure, and removal of toxins from food and animal feeds. It provides products that treat stagnation of the heart blood, obstruction of qi in the chest, cardiodynia, headache, and dysmenorrhea; upper respiratory tract infection, acute faucitis, acute tonsillitis, acute gastroenteritis, etc.; acute and chronic hepatitis, deferment hepatitis, cholecystitis, etc.; irregular menstruation, dysmenorrhea, and amenorrhea; anemia and deficiency of vital energy; palpitation, dizziness, and fatigue; and cerebral arteriosclerosis and ischemic stroke. The company distributes its products through a sales network in China. The company was formerly known as Lounsberry Holdings III, Inc. and changed its name to China Medicine Corporation in May 2006. China Medicine Corporation was founded in 2005 and is based in Guangzhou, China.Globeimmune OTCMKTS:GBIM$0.0001 0.00 (0.00%) As of 07/7/2025 11:34 AM EasternGlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado. GlobeImmune, Inc. operates as a subsidiary of ImmunityBio, Inc.Interpharm OTCMKTS:IPAHInterpharm Holdings, Inc. develops, manufactures, and markets generic prescription strength and over-the-counter pharmaceuticals. The company supplies its medicines to major retailers, wholesalers, managed care organizations, and national distributors. The company was founded in 1984 and is based in Hauppauge, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play Why Centene Stock Dropped 40% — And Whether It's a Buy Now D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.